Literature DB >> 1575351

Up-and-down regulation of skeletal muscle acetylcholine receptors. Effects on neuromuscular blockers.

J A Martyn1, D A White, G A Gronert, R S Jaffe, J M Ward.   

Abstract

Multiple factors alter the interaction of muscle relaxants with the NMJ. This review has focused on the aberrant responses caused principally by alterations in AChRs (table 1). Many pathologic states increase (up-regulate) AChR number. These include upper and lower motor neuron lesions, muscle trauma, burns, and immobilization. Pre- or postjunctional inhibition of neurotransmission by drugs or toxins also up-regulate AChRs. These include alpha- and beta-BT, NDMR, anticonvulsants, and clostridial toxins. We speculate that other bacterial toxins also up-regulate AChR. With proliferation of AChRs, agonist drug dose-response curves are shifted to the left. The exaggerated release of potassium when depolarization occurs with the use of agonists such as SCh and decamethonium can be attributed to the increased number of AChR. Thus, SCh should be avoided in patients who are in the susceptible phase (see section V). In the presence of increased AChR, the requirement for NDMR is markedly increased. Thus, the response to NDMR may be used as an indirect estimator of increased sensitivity to SCh (table 1). The most extensively studied pathologic state in which there is a decrease in AChRs is myasthenia gravis; there is immunologically mediated destruction and/or functional blockade of AChRs. The pathophysiologic and pharmacologic changes in LEMS are quite distinct from those of myasthenia gravis. Decreased AChRs in myasthenia gravis result in resistance to agonists and increased sensitivity to competitive antagonists. In conditioning exercise, the perturbed muscles show sensitivity to NDMR that may be due to decreased AChRs. Chronic elevations of ACh observed with organophosphorus poisoning or chronic use of reversible cholinesterase inhibitors results in down-regulation of AChRs. In this condition, SCh should be avoided because its metabolic breakdown would be impaired; the requirement for NDMR may be decreased. All of the varied responses to SCh and NDMR, which are associated with concomitant changes in AChRs, are analogous to drug-receptor interactions observed in other biologic systems.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1575351     DOI: 10.1097/00000542-199205000-00022

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  42 in total

Review 1.  Antiepileptic-induced resistance to neuromuscular blockers: mechanisms and clinical significance.

Authors:  Sulpicio G Soriano; J A Jeevendra Martyn
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

2.  [Not Available].

Authors:  S Siah; K Ababou; H Benziane; M Bensghir; H Bakali; A El Wali; I Ihrai; N K Drissi
Journal:  Ann Burns Fire Disasters       Date:  2008-03-31

3.  Potency of nondepolarizing muscle relaxants on muscle-type acetylcholine receptors in denervated mouse skeletal muscle.

Authors:  Hong WANG; Bin YANG; Guang-wei HAN; Shi-tong LI
Journal:  Acta Pharmacol Sin       Date:  2010-11-22       Impact factor: 6.150

4.  A single injection of botulinum toxin decreases the margin of safety of neurotransmission at local and distant sites.

Authors:  Christiane G Frick; Heidrun Fink; Manfred Blobner; Jeevendra Martyn
Journal:  Anesth Analg       Date:  2011-10-14       Impact factor: 5.108

5.  Effects of tensile stress on the alpha1 nicotinic acetylcholine receptor expression in maxillofacial skeletal myocytes.

Authors:  Xiuping Wu; Hui Gao; Danna Xiao; Songjiao Luo; Zhihe Zhao
Journal:  Mol Cell Biochem       Date:  2007-12-28       Impact factor: 3.396

6.  Immobilization with atrophy induces de novo expression of neuronal nicotinic α7 acetylcholine receptors in muscle contributing to neurotransmission.

Authors:  Sangseok Lee; Hong-Seuk Yang; Tomoki Sasakawa; Mohammed A S Khan; Ashok Khatri; Masao Kaneki; J A Jeevendra Martyn
Journal:  Anesthesiology       Date:  2014-01       Impact factor: 7.892

7.  Collaborative approach in the development of high-performance brain-computer interfaces for a neuroprosthetic arm: translation from animal models to human control.

Authors:  Jennifer L Collinger; Michael A Kryger; Richard Barbara; Timothy Betler; Kristen Bowsher; Elke H P Brown; Samuel T Clanton; Alan D Degenhart; Stephen T Foldes; Robert A Gaunt; Ferenc E Gyulai; Elizabeth A Harchick; Deborah Harrington; John B Helder; Timothy Hemmes; Matthew S Johannes; Kapil D Katyal; Geoffrey S F Ling; Angus J C McMorland; Karina Palko; Matthew P Para; Janet Scheuermann; Andrew B Schwartz; Elizabeth R Skidmore; Florian Solzbacher; Anita V Srikameswaran; Dennis P Swanson; Scott Swetz; Elizabeth C Tyler-Kabara; Meel Velliste; Wei Wang; Douglas J Weber; Brian Wodlinger; Michael L Boninger
Journal:  Clin Transl Sci       Date:  2013-08-27       Impact factor: 4.689

Review 8.  Adverse effects of depolarising neuromuscular blocking agents. Incidence, prevention and management.

Authors:  W J Book; M Abel; J B Eisenkraft
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

Review 9.  Airway management in neuroanaesthesia.

Authors:  B F Spiekermann; D J Stone; D L Bogdonoff; T A Yemen
Journal:  Can J Anaesth       Date:  1996-08       Impact factor: 5.063

10.  Chronic Escherichia coli infection induces muscle wasting without changing acetylcholine receptor numbers.

Authors:  Christiane G Frick; Heidrun Fink; Maria L Gordan; Barbara Eckel; J A Jeevendra Martyn; Manfred Blobner
Journal:  Intensive Care Med       Date:  2007-10-20       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.